Natco Pharma Limited has informed the Exchange regarding a press release dated October 17, 2025, titled "Legal update regarding Risdiplam ".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has informed the stock exchanges about a press release dated October 17, 2025, providing a legal update related to Risdiplam, a drug used in the treatment of Spinal Muscular Atrophy (SMA). The original brand version of Risdiplam is marketed globally by Roche under the name Evrysdi. While the full details of the legal update are not included in the exchange filing, it signals an ongoing legal matter concerning this molecule. Retail investors will need to refer to the company's full press release on its website for the complete details.
The outcome of this legal update could affect Natco Pharma's plans related to Risdiplam, potentially impacting its product pipeline and future revenue. Investors should watch for further clarification from the company, as legal developments in pharma often influence stock sentiment.